Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2025 (Report No. 2)
Date of Filing: December 5, 2025
This filing reports a material corporate event regarding intellectual property rather than a financial reporting period. The Company announced the receipt of a Notice of Patent Allowance in China for a novel cryogen flow control technology designed to optimize patient cryoablation outcomes.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report of a specific event and does not contain financial statements or performance metrics.
Material Changes
- Intellectual Property: Received a Notice of Patent Allowance in China for a novel cryogen flow control system.
- Strategic Impact: The patent is intended to optimize patient cryoablation outcomes, potentially strengthening the Company's competitive position in the Chinese market.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the patent allowance. No specific financial guidance or forward-looking revenue projections are included in this document.
Risks and Contingencies: The filing text does not explicitly list new risks or contingencies, though the successful commercialization of the patented technology remains subject to regulatory approvals and market acceptance.
Investor Verification Checklist
- Verify the scope and enforceability of the newly allowed patent in China.
- Review the full text of the press release (Exhibit 99.1) for technical details on the cryogen flow control technology.
- Assess the timeline for commercializing this technology in the Chinese market.
- Check subsequent filings for any financial impact or revenue recognition related to this IP milestone.